دورية أكاديمية
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
| العنوان: | Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer. |
|---|---|
| المؤلفون: | Marchiò C; Division of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy., Criscitiello C; Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Scatena C; Department of Laboratory Medicine, Pisa University Hospital, Anatomic Pathology 1 Universitaria, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy., Santinelli A; Anatomic Pathology, Azienda Sanitaria Territoriale di Pesaro-Urbino, Pesaro, Italy., Graziano P; Pathology Unit, Fondazione IRCCS Ospedale 'Casa Sollievo della Sofferenza', San Giovanni Rotondo (FG), Italy., Malapelle U; Department of Public Health, Federico II University of Naples, Naples, Italy., Cursano G; Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Venetis K; Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Fanelli GN; Department of Laboratory Medicine, Pisa University Hospital, Anatomic Pathology 1 Universitaria, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy., Pepe F; Department of Public Health, Federico II University of Naples, Naples, Italy., Berrino E; Division of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy., Angelis C; Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy., Perrone G; Department of Medicine and Surgery, Research Unit of Anatomical Pathology, Università Campus Bio-Medico di Roma, Roma, Italy.; Anatomical Pathology Operative Research Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy., Curigliano G; Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Fusco N; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Pathology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. |
| المصدر: | Pathologica [Pathologica] 2023 Dec; Vol. 115 (6), pp. 292-301. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pacini Editore SpA Country of Publication: Italy NLM ID: 0401123 Publication Model: Print Cited Medium: Internet ISSN: 1591-951X (Electronic) Linking ISSN: 00312983 NLM ISO Abbreviation: Pathologica Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2007-> : Ospedaletto, Psia : Pacini Editore SpA Original Publication: Genova : [s.n.] |
| مواضيع طبية MeSH: | Artificial Intelligence* , Breast Neoplasms*/diagnosis , Breast Neoplasms*/genetics, Humans ; Female ; Reproducibility of Results ; Pathologists |
| مستخلص: | This work explores the complex field of HER2 testing in the HER2-low breast cancer era, with a focus on methodological aspects. We aim to propose clear positions to scientific societies, institutions, pathologists, and oncologists to guide and shape the appropriate diagnostic strategies for HER2-low breast cancer. The fundamental question at hand is whether the necessary tools to effectively translate our knowledge about HER2 into practical diagnostic schemes for the lower spectrum of expression are available. Our investigation is centered on the significance of distinguishing between an immunohistochemistry (IHC) score 0 and score 1+ in light of the clinical implications now apparent, as patients with HER2-low breast cancer become eligible for trastuzumab-deruxtecan treatment. Furthermore, we discuss the definition of HER2-low beyond its conventional boundaries and assess the reliability of established diagnostic procedures designed at a time when therapeutic perspectives were non-existent for these cases. In this regard, we examine potential complementary technologies, such as gene expression analysis and liquid biopsy. Ultimately, we consider the potential role of artificial intelligence (AI) in the field of digital pathology and its integration into HER2 testing, with a particular emphasis on its application in the context of HER2-low breast cancer. (Copyright © 2023 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.) |
| References: | Br J Cancer. 2023 Nov;129(10):1692-1705. (PMID: 37740038) J Clin Oncol. 2023 Aug 1;41(22):3867-3872. (PMID: 37284804) Lab Invest. 2017 Dec;97(12):1521-1526. (PMID: 28892092) J Mol Diagn. 2004 Feb;6(1):42-51. (PMID: 14736826) J Clin Med. 2020 Nov 18;9(11):. (PMID: 33217963) J Clin Oncol. 2018 Jul 10;36(20):2105-2122. (PMID: 29846122) Cancers (Basel). 2023 Apr 26;15(9):. (PMID: 37173958) Target Oncol. 2023 May;18(3):313-319. (PMID: 37133651) Eur J Cancer Prev. 2023 Sep 1;32(5):460-467. (PMID: 37038997) N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782) Cancers (Basel). 2021 May 28;13(11):. (PMID: 34071230) Ann Oncol. 2023 Aug;34(8):645-659. (PMID: 37269905) Int Rev Cell Mol Biol. 2023;381:1-21. (PMID: 37739480) Crit Rev Oncol Hematol. 2023 Oct;190:104103. (PMID: 37595344) J Pathol Inform. 2022 Jul 05;13:100116. (PMID: 36268099) Histol Histopathol. 2021 Dec;36(12):1235-1245. (PMID: 34585734) Mol Cancer. 2022 Mar 18;21(1):79. (PMID: 35303879) Am J Surg Pathol. 2018 Sep;42(9):1190-1200. (PMID: 29975246) Br J Cancer. 2023 Jul;129(1):122-134. (PMID: 37120672) Nat Med. 2023 Aug;29(8):2110-2120. (PMID: 37488289) Anticancer Res. 2005 May-Jun;25(3B):1895-900. (PMID: 16158923) Pathologica. 2022 Apr;114(2):104-110. (PMID: 35414722) Front Oncol. 2021 Jul 16;11:698551. (PMID: 34336686) Ann Oncol. 2016 Oct;27(10):1867-73. (PMID: 27484801) Genome Med. 2022 Aug 29;14(1):98. (PMID: 36038884) Front Oncol. 2023 Apr 28;13:1053125. (PMID: 37188174) JAMA Oncol. 2022 Apr 01;8(4):1-4. (PMID: 35113160) J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045) Toxicol Pathol. 2021 Jun;49(4):755-772. (PMID: 33251977) ESMO Open. 2021 Dec;6(6):100299. (PMID: 34839105) Gene. 2017 Mar 20;605:114-122. (PMID: 28039034) Cancer Treat Rev. 2020 Mar;84:101965. (PMID: 32000054) Histopathology. 2019 Jul;75(1):39-53. (PMID: 30801768) Am J Clin Pathol. 2015 Nov;144(5):686-703. (PMID: 26486732) Front Mol Biosci. 2023 Apr 03;10:1176309. (PMID: 37077201) ESMO Open. 2023 Aug;8(4):101615. (PMID: 37562195) Mod Pathol. 2023 Mar;36(3):100054. (PMID: 36788100) Cancer Drug Resist. 2022 Sep 1;5(4):882-888. (PMID: 36627898) Eur J Cancer. 2023 Jul;188:152-160. (PMID: 37247580) J Clin Oncol. 2020 Feb 10;38(5):444-453. (PMID: 31821109) NPJ Breast Cancer. 2021 Jan 4;7(1):1. (PMID: 33397968) Ther Adv Med Oncol. 2023 Feb 9;15:17588359231152842. (PMID: 36844387) Virchows Arch. 2022 Nov;481(5):685-694. (PMID: 35970977) Semin Cancer Biol. 2021 Jul;72:123-135. (PMID: 32112814) Mol Diagn Ther. 2022 Jan;26(1):105-116. (PMID: 34932189) Virchows Arch. 2023 Sep 28;:. (PMID: 37770765) Breast. 2023 Feb;67:116-123. (PMID: 36669993) J Pers Med. 2023 Sep 16;13(9):. (PMID: 37763157) Mol Cancer. 2022 Jan 20;21(1):25. (PMID: 35057806) NPJ Breast Cancer. 2021 Oct 12;7(1):137. (PMID: 34642348) Front Mol Biosci. 2022 Mar 15;9:834651. (PMID: 35372498) Nat Rev Clin Oncol. 2021 Jun;18(6):327-344. (PMID: 33558752) J Clin Oncol. 2011 Feb 1;29(4):398-405. (PMID: 21172893) J Clin Oncol. 2011 Nov 10;29(32):4219-21. (PMID: 21990408) BMC Med. 2011 Apr 19;9:41. (PMID: 21504565) J Transl Med. 2017 May 1;15(1):91. (PMID: 28460632) Ann Oncol. 2023 Oct;34(10):949-950. (PMID: 37499870) J Breast Cancer. 2017 Sep;20(3):286-296. (PMID: 28970855) Histopathology. 2023 May;82(6):912-924. (PMID: 36737248) Breast Cancer Res. 2021 Dec 14;23(1):112. (PMID: 34906198) Biomark Res. 2022 Aug 13;10(1):58. (PMID: 35962400) Int Rev Cell Mol Biol. 2023;381:23-56. (PMID: 37739483) J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. (PMID: 31037288) Diagnostics (Basel). 2023 Jan 03;13(1):. (PMID: 36611460) |
| فهرسة مساهمة: | Keywords: Artificial Intelligence; HER2-low; breast cancer; liquid biopsy; pathology; testing methods |
| تواريخ الأحداث: | Date Created: 20240105 Date Completed: 20240108 Latest Revision: 20240108 |
| رمز التحديث: | 20240108 |
| مُعرف محوري في PubMed: | PMC10767801 |
| DOI: | 10.32074/1591-951X-942 |
| PMID: | 38180137 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1591-951X |
|---|---|
| DOI: | 10.32074/1591-951X-942 |